IDEXX LABORATORIES INC (IDXX) Stock Fundamental Analysis
USA - NASDAQ:IDXX - US45168D1046 - Common Stock
713.74 USD
-6.47 (-0.9%)
713.74 USD
0 (0%)
We assign a fundamental rating of 7 out of 10 to IDXX. IDXX was compared to 189 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making IDXX a very profitable company, without any liquidiy or solvency issues. IDXX has a decent growth rate and is not valued too expensively. With these ratings, IDXX could be worth investigating further for quality investing!.
1. Profitability
1.1 Basic Checks
IDXX had positive earnings in the past year.
IDXX had a positive operating cash flow in the past year.
IDXX had positive earnings in each of the past 5 years.
Each year in the past 5 years IDXX had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 30.34%, IDXX belongs to the best of the industry, outperforming 98.94% of the companies in the same industry.
IDXX has a Return On Equity of 65.81%. This is amongst the best in the industry. IDXX outperforms 99.47% of its industry peers.
IDXX's Return On Invested Capital of 40.25% is amongst the best of the industry. IDXX outperforms 99.47% of its industry peers.
IDXX had an Average Return On Invested Capital over the past 3 years of 35.08%. This is significantly above the industry average of 9.12%.
The 3 year average ROIC (35.08%) for IDXX is below the current ROIC(40.25%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.34% | ||
| ROE | 65.81% | ||
| ROIC | 40.25% |
ROA(3y)25.87%
ROA(5y)26.7%
ROE(3y)74.71%
ROE(5y)84.83%
ROIC(3y)35.08%
ROIC(5y)36.07%
1.3 Margins
With an excellent Profit Margin value of 24.65%, IDXX belongs to the best of the industry, outperforming 94.18% of the companies in the same industry.
IDXX's Profit Margin has improved in the last couple of years.
IDXX has a Operating Margin of 31.34%. This is amongst the best in the industry. IDXX outperforms 97.88% of its industry peers.
IDXX's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 61.72%, IDXX is in the better half of the industry, outperforming 63.49% of the companies in the same industry.
IDXX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.34% | ||
| PM (TTM) | 24.65% | ||
| GM | 61.72% |
OM growth 3Y0.02%
OM growth 5Y4.78%
PM growth 3Y-0.56%
PM growth 5Y5.09%
GM growth 3Y1.27%
GM growth 5Y1.47%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), IDXX is creating value.
IDXX has less shares outstanding than it did 1 year ago.
The number of shares outstanding for IDXX has been reduced compared to 5 years ago.
The debt/assets ratio for IDXX has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 24.06 indicates that IDXX is not in any danger for bankruptcy at the moment.
IDXX has a Altman-Z score of 24.06. This is amongst the best in the industry. IDXX outperforms 96.30% of its industry peers.
IDXX has a debt to FCF ratio of 1.04. This is a very positive value and a sign of high solvency as it would only need 1.04 years to pay back of all of its debts.
IDXX has a better Debt to FCF ratio (1.04) than 91.01% of its industry peers.
A Debt/Equity ratio of 0.53 indicates that IDXX is somewhat dependend on debt financing.
IDXX has a Debt to Equity ratio (0.53) which is comparable to the rest of the industry.
Although IDXX does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 1.04 | ||
| Altman-Z | 24.06 |
ROIC/WACC4.44
WACC9.07%
2.3 Liquidity
A Current Ratio of 1.18 indicates that IDXX should not have too much problems paying its short term obligations.
With a Current ratio value of 1.18, IDXX is not doing good in the industry: 83.60% of the companies in the same industry are doing better.
A Quick Ratio of 0.87 indicates that IDXX may have some problems paying its short term obligations.
IDXX has a worse Quick ratio (0.87) than 83.07% of its industry peers.
IDXX does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.18 | ||
| Quick Ratio | 0.87 |
3. Growth
3.1 Past
IDXX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.16%, which is quite good.
Measured over the past years, IDXX shows a quite strong growth in Earnings Per Share. The EPS has been growing by 18.18% on average per year.
IDXX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 8.39%.
Measured over the past years, IDXX shows a quite strong growth in Revenue. The Revenue has been growing by 10.12% on average per year.
EPS 1Y (TTM)15.16%
EPS 3Y9.32%
EPS 5Y18.18%
EPS Q2Q%21.43%
Revenue 1Y (TTM)8.39%
Revenue growth 3Y6.62%
Revenue growth 5Y10.12%
Sales Q2Q%13.29%
3.2 Future
Based on estimates for the next years, IDXX will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.68% on average per year.
IDXX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.69% yearly.
EPS Next Y14.37%
EPS Next 2Y13.33%
EPS Next 3Y13.16%
EPS Next 5Y11.68%
Revenue Next Year9.1%
Revenue Next 2Y8.66%
Revenue Next 3Y8.63%
Revenue Next 5Y8.69%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 56.60, the valuation of IDXX can be described as expensive.
Based on the Price/Earnings ratio, IDXX is valued a bit cheaper than 67.72% of the companies in the same industry.
IDXX is valuated expensively when we compare the Price/Earnings ratio to 26.13, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 49.40 indicates a quite expensive valuation of IDXX.
Based on the Price/Forward Earnings ratio, IDXX is valued a bit cheaper than the industry average as 69.31% of the companies are valued more expensively.
IDXX's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.35.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 56.6 | ||
| Fwd PE | 49.4 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of IDXX indicates a somewhat cheap valuation: IDXX is cheaper than 68.78% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, IDXX is valued a bit cheaper than the industry average as 73.02% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 60.73 | ||
| EV/EBITDA | 40.06 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
IDXX has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as IDXX's earnings are expected to grow with 13.16% in the coming years.
PEG (NY)3.94
PEG (5Y)3.11
EPS Next 2Y13.33%
EPS Next 3Y13.16%
5. Dividend
5.1 Amount
No dividends for IDXX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
713.74
-6.47 (-0.9%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners97.04%
Inst Owner Change-0.8%
Ins Owners0.2%
Ins Owner Change2.22%
Market Cap57.10B
Revenue(TTM)4.17B
Net Income(TTM)1.03B
Analysts80
Price Target697.54 (-2.27%)
Short Float %2.24%
Short Ratio4.35
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.14%
Min EPS beat(2)6.47%
Max EPS beat(2)7.81%
EPS beat(4)4
Avg EPS beat(4)5.72%
Min EPS beat(4)1.72%
Max EPS beat(4)7.81%
EPS beat(8)8
Avg EPS beat(8)4.83%
EPS beat(12)12
Avg EPS beat(12)4.67%
EPS beat(16)14
Avg EPS beat(16)4.04%
Revenue beat(2)2
Avg Revenue beat(2)1.45%
Min Revenue beat(2)1.03%
Max Revenue beat(2)1.88%
Revenue beat(4)3
Avg Revenue beat(4)0.26%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)1.88%
Revenue beat(8)3
Avg Revenue beat(8)-0.81%
Revenue beat(12)3
Avg Revenue beat(12)-1.06%
Revenue beat(16)4
Avg Revenue beat(16)-1.1%
PT rev (1m)0.88%
PT rev (3m)28.71%
EPS NQ rev (1m)0.16%
EPS NQ rev (3m)1.03%
EPS NY rev (1m)0.13%
EPS NY rev (3m)3.64%
Revenue NQ rev (1m)0.09%
Revenue NQ rev (3m)2.15%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)2.01%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 56.6 | ||
| Fwd PE | 49.4 | ||
| P/S | 13.7 | ||
| P/FCF | 60.73 | ||
| P/OCF | 52.48 | ||
| P/B | 36.57 | ||
| P/tB | 55.29 | ||
| EV/EBITDA | 40.06 |
EPS(TTM)12.61
EY1.77%
EPS(NY)14.45
Fwd EY2.02%
FCF(TTM)11.75
FCFY1.65%
OCF(TTM)13.6
OCFY1.91%
SpS52.09
BVpS19.51
TBVpS12.91
PEG (NY)3.94
PEG (5Y)3.11
Graham Number74.41
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.34% | ||
| ROE | 65.81% | ||
| ROCE | 61.18% | ||
| ROIC | 40.25% | ||
| ROICexc | 43.77% | ||
| ROICexgc | 56.25% | ||
| OM | 31.34% | ||
| PM (TTM) | 24.65% | ||
| GM | 61.72% | ||
| FCFM | 22.56% |
ROA(3y)25.87%
ROA(5y)26.7%
ROE(3y)74.71%
ROE(5y)84.83%
ROIC(3y)35.08%
ROIC(5y)36.07%
ROICexc(3y)39.8%
ROICexc(5y)41.54%
ROICexgc(3y)51.52%
ROICexgc(5y)54.7%
ROCE(3y)52.73%
ROCE(5y)50.92%
ROICexgc growth 3Y-5.99%
ROICexgc growth 5Y4.28%
ROICexc growth 3Y-3.86%
ROICexc growth 5Y4.07%
OM growth 3Y0.02%
OM growth 5Y4.78%
PM growth 3Y-0.56%
PM growth 5Y5.09%
GM growth 3Y1.27%
GM growth 5Y1.47%
F-Score8
Asset Turnover1.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 1.04 | ||
| Debt/EBITDA | 0.57 | ||
| Cap/Depr | 105.48% | ||
| Cap/Sales | 3.55% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 75.23% | ||
| Profit Quality | 91.51% | ||
| Current Ratio | 1.18 | ||
| Quick Ratio | 0.87 | ||
| Altman-Z | 24.06 |
F-Score8
WACC9.07%
ROIC/WACC4.44
Cap/Depr(3y)119.67%
Cap/Depr(5y)117.13%
Cap/Sales(3y)3.91%
Cap/Sales(5y)3.89%
Profit Quality(3y)79.31%
Profit Quality(5y)83.23%
High Growth Momentum
Growth
EPS 1Y (TTM)15.16%
EPS 3Y9.32%
EPS 5Y18.18%
EPS Q2Q%21.43%
EPS Next Y14.37%
EPS Next 2Y13.33%
EPS Next 3Y13.16%
EPS Next 5Y11.68%
Revenue 1Y (TTM)8.39%
Revenue growth 3Y6.62%
Revenue growth 5Y10.12%
Sales Q2Q%13.29%
Revenue Next Year9.1%
Revenue Next 2Y8.66%
Revenue Next 3Y8.63%
Revenue Next 5Y8.69%
EBIT growth 1Y17.46%
EBIT growth 3Y6.64%
EBIT growth 5Y15.38%
EBIT Next Year31.91%
EBIT Next 3Y16.8%
EBIT Next 5Y14.07%
FCF growth 1Y38.31%
FCF growth 3Y7.86%
FCF growth 5Y21.3%
OCF growth 1Y31.08%
OCF growth 3Y7.13%
OCF growth 5Y15.14%
IDEXX LABORATORIES INC / IDXX FAQ
What is the ChartMill fundamental rating of IDEXX LABORATORIES INC (IDXX) stock?
ChartMill assigns a fundamental rating of 7 / 10 to IDXX.
Can you provide the valuation status for IDEXX LABORATORIES INC?
ChartMill assigns a valuation rating of 4 / 10 to IDEXX LABORATORIES INC (IDXX). This can be considered as Fairly Valued.
Can you provide the profitability details for IDEXX LABORATORIES INC?
IDEXX LABORATORIES INC (IDXX) has a profitability rating of 9 / 10.
What is the valuation of IDEXX LABORATORIES INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for IDEXX LABORATORIES INC (IDXX) is 56.6 and the Price/Book (PB) ratio is 36.57.
Can you provide the expected EPS growth for IDXX stock?
The Earnings per Share (EPS) of IDEXX LABORATORIES INC (IDXX) is expected to grow by 14.37% in the next year.